Hey there,
The new A.I. upgrades to MarketBeat All Access are getting incredible results, and I want to make sure you don't miss out.
I'm not talking about minor tweaks or cosmetic changes. We've fundamentally transformed how our platform analyzes markets, identifies opportunities, and delivers insights. This is the biggest upgrade in MarketBeat's history.
Your free 30-day trial is ready whenever you are:
You'll get instant access to:
- Advanced A.I. tools for portfolio analysis
- The upgraded Idea Engine™ with A.I. enhancements
- Premium research reports exclusive to All Access subscribers
- Real-time alerts powered by intelligent analysis
Plus, you get access to our complete suite: Momentum Alerts, Live News Feed, advanced screeners, 1 Million+ historical analyst ratings, proprietary reports, premium articles, and priority support.
Look, I know there are a lot of "A.I." tools out there making big promises. Most of them are just marketing gimmicks slapped onto existing products. This is different. We've spent significant resources building real A.I. capabilities that deliver measurable results.
The 30-day trial is completely free. This isn't a stripped-down trial – you get full access to everything, and if you don't see the value, you can cancel with one click.
But here's the thing: once you experience what A.I.-enhanced investing feels like, you'll never want to go back to doing research the old way.
Matthew Paulson
CEO, MarketBeat
3 Healthcare Stocks Using AI to Drive Growth
Written by Chris Markoch. Published 9/27/2025.
Key Points
- Discover how three healthcare companies use AI to improve patient outcomes and reduce physician burnout.
- Learn why Hims & Hers, Tempus AI, and Boston Scientific are positioned for growth as AI adoption accelerates.
- See how AI is transforming telehealth, precision medicine, and medical devices to drive efficiency in healthcare.
Artificial intelligence (AI) is transforming the world much like the internet did 30 years ago. This change goes beyond search: AI is revolutionizing how industries handle administrative tasks, and healthcare is among the most impacted sectors.
Generative and agentic AI are enabling physicians and care teams to make more accurate diagnoses, automate routine tasks, and alleviate provider burnout. According to Athenahealth's third Physician Sentiment Survey (PSS), 93% of physicians report feeling burned out on a regular basis.
Get Ahead with This Free Report! (Ad)
Verastem Inc. surged 1,670%—from just $0.32 to $5.68. Early investors who spotted the opportunity before the crowd saw extraordinary gains.
Now, Stock News Trends is releasing its new Wealth Building Report, featuring little-known companies with breakout potential for 2025. This expert research is available 100% free—but only for a limited time.
With an aging population intensifying the existing supply–demand imbalance, AI can help bridge the gap between efficiency and personalized care.
Investors seeking exposure to this trend should look at companies already leveraging AI to boost outcomes and streamline operations. Here are three healthcare stocks poised for future growth thanks to AI-driven catalysts.
AI-Enhanced Telehealth at Scale
Hims & Hers Health Inc. (NYSE: HIMS) has been one of the best-performing stocks in 2025, climbing 121% year to date and 29% over the 30 days ending September 24. While the meme-stock crowd may have fueled some of those gains, the company's underlying growth story remains compelling for long-term investors.
As a telehealth provider, Hims & Hers was designed to embrace digital solutions. Eliminating inefficiencies is essential for scaling virtual care, and Hims uses AI to automate triaging patient concerns, send follow-up reminders and streamline prescription refills.
At $53.86 per share as of this writing, HIMS shares sit about 21% below their February high and have twice encountered resistance around $65. Elevated trading volume—driven in part by short sellers—has amplified price swings.
That volatility aside, analysts assign HIMS a consensus Hold rating. On September 12, however, Canaccord Genuity reiterated a Buy rating and set a $68 price target. Careful timing could allow investors to ride a strong AI-driven tailwind.
Precision Medicine and Oncology Insights
Tempus AI (NASDAQ: TEM) is another healthcare innovator using AI and machine learning to analyze genomic, clinical and molecular data for precision medicine. Its oncology focus provides a powerful catalyst: Tempus's tools help physicians tailor cancer treatment plans, predict patient outcomes and identify real-time clinical trial opportunities.
Beyond the clinic, 19 of the world's top 20 pharmaceutical companies rely on Tempus data for drug discovery. In September, Tempus secured 510(k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR IVD device, enhancing RNA sequencing capabilities for its partners.
Like HIMS, TEM stock has exhibited volatility—up 128% in 2025 and 17% over the past three months—while carrying more than 25% short interest and facing resistance near its $89 all-time high. Yet analysts remain optimistic, raising price targets on a stock backed by one of healthcare's fastest-growing AI platforms.
Smarter Devices with AI Integration
Boston Scientific Corp. (NYSE: BSX) is leveraging AI to streamline data processing and enhance its medical-device portfolio. Its digital health solutions automate monitoring and diagnostic tasks, freeing clinicians to focus on direct patient care.
A recent catalyst was the FDA approval of its FARAPULSE pulsed field ablation system for expanded use in treating certain forms of atrial fibrillation—a condition affecting nearly 60 million people worldwide. Following the announcement, at least two analysts reiterated Buy ratings on BSX and set price targets well above the consensus.
BSX shares have gained about 17% in 2025, roughly in line with the S&P 500, but the stock has struggled to surpass its 52-week high compared with its higher-flying peers.
We empower investors to make better financial decisions by delivering up-to-the-minute financial information and objective investment analysis.
If you have questions or concerns about your subscription, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Suite 620, Sioux Falls, South Dakota 57103-7078. U.S.A..
No comments:
Post a Comment